Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Varian Medical Systems (VAR) Stock Price
News headlines about Varian Medical Systems (NYSE:VAR) have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Varian Medical Systems earned a news impact score of 0.18 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 46.1692862044144 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s analysis:
- Global Radiotherapy Market to 2023 – Rising Incidence and Prevalence of Cancer & Rising Technological Advancements (bizjournals.com)
- Varian Medical Systems (VAR) Rating Reiterated by Royal Bank Of Canada (americanbankingnews.com)
- Radiotherapy Market Size | Global Industry Report 2016 to 2021 (emailwire.com)
- Proton Therapy Market Analysis, Segments, Growth and Value Chain 2017 – 2025 (dcvelocity.com)
- Global Radiotherapy Market Research Report 2017 – 2023 – Research and Markets (businesswire.com)
Several equities analysts recently weighed in on VAR shares. Royal Bank Of Canada restated a “hold” rating and set a $100.00 target price on shares of Varian Medical Systems in a report on Friday, September 1st. Robert W. Baird reaffirmed a “hold” rating and set a $99.00 price target on shares of Varian Medical Systems in a research note on Monday, August 28th. BidaskClub raised shares of Varian Medical Systems from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. BTIG Research reaffirmed a “hold” rating on shares of Varian Medical Systems in a research note on Sunday, October 29th. Finally, Citigroup lifted their price target on shares of Varian Medical Systems from $119.00 to $121.00 and gave the stock a “neutral” rating in a research note on Monday, October 30th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $98.39.
Varian Medical Systems (VAR) traded up $0.53 on Thursday, hitting $111.75. 1,618,400 shares of the stock traded hands, compared to its average volume of 867,186. The company has a market cap of $10,034.80, a P/E ratio of 29.05, a P/E/G ratio of 3.22 and a beta of 0.65. Varian Medical Systems has a one year low of $76.94 and a one year high of $112.45.
Varian Medical Systems (NYSE:VAR) last released its earnings results on Wednesday, October 25th. The medical equipment provider reported $1.09 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.19 by ($0.10). The company had revenue of $739.00 million during the quarter, compared to the consensus estimate of $741.69 million. Varian Medical Systems had a return on equity of 23.68% and a net margin of 8.85%. Varian Medical Systems’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.03 EPS. analysts anticipate that Varian Medical Systems will post 4.26 earnings per share for the current year.
In related news, EVP Kolleen T. Kennedy sold 2,021 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $107.36, for a total transaction of $216,974.56. Following the completion of the sale, the executive vice president now owns 27,595 shares of the company’s stock, valued at approximately $2,962,599.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Kolleen T. Kennedy sold 931 shares of the business’s stock in a transaction dated Wednesday, October 18th. The shares were sold at an average price of $105.00, for a total transaction of $97,755.00. Following the sale, the executive vice president now directly owns 27,531 shares of the company’s stock, valued at approximately $2,890,755. The disclosure for this sale can be found here. Insiders sold a total of 41,830 shares of company stock valued at $4,350,109 in the last three months. Insiders own 0.91% of the company’s stock.
About Varian Medical Systems
Varian Medical Systems, Inc is a manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy.
Receive News & Ratings for Varian Medical Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Varian Medical Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.